GlassScriptPhysician profile
Barbara C Lipschitz
NPI 1215097472
$636.79
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $105 · 2021: $133 · 2022: $267.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $152.20 | 2020-2022 | |
| Abbvie INC. | $122.24 | 2020-2022 | |
| Amgen INC. | $82.64 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $70.06 | 2019-2022 | |
| Allergan, INC. | $41.23 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.21 | 2021 | |
| Astellas Pharma US INC | $23.85 | 2019 | |
| Abbott Laboratories | $17.76 | 2019 | |
| Novo Nordisk INC | $15.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.98 | 2022 | |
| Pfizer INC. | $13.75 | 2020 | |
| Gilead Sciences, INC. | $13.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Lipschitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.